Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ: BGNE )

181.62 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer
Via Benzinga
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will... 
Via Talk Markets
BeiGene Earnings Perspective: Return On Capital Employed
Via Benzinga
What 5 Analyst Ratings Have To Say About BeiGene
Via Benzinga
Will Investors Notice Exciting Sign On BeiGene's Chart?
Via Benzinga
Why Shares of BeiGene Were Up Wednesday
The Chinese pharmaceutical stock is experiencing a comeback. 
Via The Motley Fool
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
From BeiGene
Via Business Wire
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
From BeiGene
Via Business Wire
What 4 Analyst Ratings Have To Say About BeiGene
Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter: 
Via Benzinga
Is This Chinese Pharmaceutical Stock Worth the Risk?
BeiGene's shares are down this year, but it has two potential blockbusters. 
Via The Motley Fool
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier. 
Via Investor's Business Daily
Why Leslie's Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday's Mid-Day Session
Gainers Biophytis S.A. (NASDAQ: BPTS) shares jumped 114% to $0.7496. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) rose 74.1% to $0.2115. 
Via Benzinga
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket
Gainers Kalera Public Limited Company (NASDAQ: KAL) shares rose 33.3% to $0.2399 in pre-market trading after jumping 45% on Tuesday. Kalera recently announced restructuring process for German... 
Via Benzinga
Dollar Tree, Dycom Industries, Chico's FAS And Other Big Losers From Tuesday
U.S. stocks closed higher on Tuesday, with the Dow Jones gaining around 400 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
From BeiGene
Via Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
From BeiGene
Via Business Wire
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
From BeiGene
Via Business Wire
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
From BeiGene
Via Business Wire
Tesla, Amazon, Coupang, Rivian, Beigene: Musk's Share Sale, Antitrust Lawsuit, Earnings Grab Retail Investors' Eyeballs
Major Wall Street indices closed nearly 2% lower on Wednesday after the day was marred by uncertainties including the outcome of the mid-term elections and a sell-off in the cryptocurrency... 
Via Benzinga
BeiGene Reports Third Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
From BeiGene
Via Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
From BeiGene
Via Business Wire
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
From BeiGene
Via Business Wire
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal
Via Benzinga
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.